about
In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I MetabolitesPhotochemical stability of nimesulide.Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats.LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH)Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injuryAroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications.Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity.Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor.Dimethylamino acid esters as biodegradable and reversible transdermal permeation enhancers: effects of linking chain length, chirality and polyfluorination.Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites--the cardioprotectant dexrazoxane as a model case.Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT.Chromatographic methods for the separation of biocompatible iron chelators from their synthetic precursors and iron chelates.LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT.HPLC study on stability of pyridoxal isonicotinoyl hydrazone.Investigation of the stability of aromatic hydrazones in plasma and related biological material.Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart.Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.Deferoxamine but not Dexrazoxane Alleviates Liver Injury Induced by Endotoxemia in RatsEnhanced Topical and Transdermal Delivery of Antineoplastic and Antiviral Acyclic Nucleoside Phosphonate cPr-PMEDAPIdentification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography–quadrupole-time-of-flight mass spectrometryDevelopment and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activityUHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation studyDetermination of lipophilicity of novel potential antituberculotic agents using HPLC on monolithic stationary phase and theoretical calculationsUse of different stationary phases for separation of isoniazid, its metabolites and vitamin B6 formsThe retention behaviour of polar compounds on zirconia based stationary phases under hydrophilic interaction liquid chromatography conditionsDevelopment of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture mediumInterface-free capillary electrophoresis-mass spectrometry system with nanospray ionization-Analysis of dexrazoxane in blood plasmaStructure-Activity Relationships of Nitro-Substituted Aroylhydrazone Iron Chelators with Antioxidant and Antiproliferative ActivitiesInvestigation of structure-activity relationships of dexrazoxane analogues reveals topoisomerase IIβ interaction as a prerequisite for effective protection against anthracycline cardiotoxicityZirconia--a stationary phase capable of the separation of polar markers of myocardial metabolism in hydrophilic interaction chromatography
P50
Q28550205-5BA578D7-611C-48AE-878E-14A3B2990EA4Q34532184-AF5B2016-F6A1-4D35-AF98-0F00D642C9FDQ35047321-B382D851-2E01-4DE2-B2D1-EE9B197394B9Q35071893-6645306E-C3E3-494E-BB7F-B77BD40F3187Q35418008-D5511B2E-F99C-46C8-B98C-E8D3B169B76EQ36568908-FD38096C-A4EA-4ED1-8F76-D99C76F90787Q36618876-B516A94C-21A5-48F6-B0EE-DB354702E3C5Q36957543-8283CE17-2716-4C42-9BE4-164745298323Q38732745-AA508274-C788-4860-B53B-CA6C161D037BQ38741123-AA9B98D3-ABD8-4BBE-B8F7-C017309BCA41Q38770392-D4C50377-51B5-468D-B29C-0639C9ED49E3Q39361260-B23B43C2-1A4A-42D2-86C4-626B542673D8Q39485305-9F3ADA51-D4D7-4221-AB27-CE7BDFCB1ABAQ39621619-7AC883D0-3B35-483A-BF66-9E5C1DB4CAD8Q39696938-D27ABF5A-8780-452F-BBA5-6E00A6D6AC6DQ39905552-1E5C65AC-0169-444C-B000-1AC9D2EEF535Q40027942-ABBB52F4-2624-418B-8B4A-FA3F8BA7ABE0Q42683565-9AAD1640-4659-4F7E-AC08-E00A71289F09Q43176490-CB264E15-D976-47DB-964A-4333264F9EC8Q45215411-17ACBCDE-4290-48FE-9780-553B28D4E48DQ45228449-DAF49ECC-FE2F-4ADF-8473-A9464839DF13Q46629877-96F30047-0CC3-40CF-810D-3B66B87BE16BQ46737790-7A2651D6-873F-4A0B-94AB-FD07D3A82115Q47256495-F0588DF8-BE72-4B6C-A8C7-975544478117Q47932775-67C395CF-30D2-477C-B194-CC560E017155Q54601099-82B9F977-6D58-4624-9718-070AD569B683Q60496417-AC8B2BA6-7631-4343-8472-59531242F621Q61050462-D6DC7739-7612-4DB8-B9C8-2241970C88FBQ61050475-BE7C143E-DC74-49FF-A777-1811A51A2A73Q64096040-C9B279D9-C1AB-4BC2-B337-59395971498CQ80693487-977CD04F-09A3-4674-B44D-50363B03B0D9Q84092236-67C0BEC7-7EE4-46A8-8B72-485E8893AAC8Q84862699-D0654842-B1F8-4CE9-997F-3E28B8B082ADQ85935709-1D788389-7091-4BDC-B284-6D54C168F73FQ88305288-A942AF67-303A-4AEF-B151-9F7F2ED8C264Q88689182-C385A62E-0D41-4AA3-97D3-7EC8055FCD84Q91610451-72F29356-C411-407F-8D85-026694D70A46Q95561461-C55F7F00-4002-4B5F-A73F-60AE8723FF0E
P50
description
researcher
@en
wetenschapper
@nl
name
Petra Kovaríková
@en
Petra Kovaríková
@nl
type
label
Petra Kovaríková
@en
Petra Kovaríková
@nl
prefLabel
Petra Kovaríková
@en
Petra Kovaríková
@nl
P106
P31
P496
0000-0002-1242-5706